Article Text

Download PDFPDF
Clinical benefit of R-CHOP without splenectomy in stage I primary splenic diffuse large B-cell lymphoma
  1. Tara Rajendran1,
  2. Jyoti Ramanath Kini2,
  3. Aysha Abna3 and
  4. Krishna Prasad1,4
  1. 1Division of Medical Oncology, Department of General Medicine, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Mangalore, Karnataka, India
  2. 2Department of Pathology, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Mangalore, Karnataka, India
  3. 3Department of Radio-diagnosis and Imaging, Father Muller Medical College, Mangalore, Karnataka, India
  4. 4Department of Medical Oncology, Mangalore Institute of Oncology, Mangalore, Karnataka, India
  1. Correspondence to Dr Tara Rajendran; tara.mankara{at}gmail.com

Abstract

Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) is a relatively rare malignancy, and there are no optimal approaches for diagnosis and management. There are less invasive splenic biopsies that effectively obviate diagnostic and elective splenectomies. We report a man in his 50s with 2-day history of pain in the abdomen and who was found to have a splenic mass on PET-CT. A CT-guided core needle splenic biopsy confirmed the diagnosis of PS-DLBCL. He was managed with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) alone, without splenectomy. The patient attained complete remission, and he is disease free at 6 years of follow-up.

  • haematology (incl blood transfusion)
  • oncology
  • cancer intervention
  • malignant and benign haematology
  • chemotherapy

Statistics from Altmetric.com

Footnotes

  • Twitter @TaraRajendran, @JR_Kini

  • Contributors TR did the conceptualisation, methodology, data curation and original draft preparation. JRK wrote the pathology section of the original draft and AA wrote the radiology section of the manuscript. KP did the investigation, supervision, reviewing and editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests KP has stock and other ownership interests at Merck and NATCO and receives honoraria from AstraZeneca; Cipla; DR.REDDYS; Mylan.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.